Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia

Supportive Care in Cancer

Volumn 20, Issue 12, 2012, Pages 3255-3260

  Van Den Hurk, C J G ^a,b   Breed, W P M ^a   Nortier, J W R ^a  

^a The Netherlands   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy induced alopecia; Docetaxel; Hair loss; Post infusion cooling time; Scalp cooling; Supportive care

Indexed keywords

CAPECITABINE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; TRASTUZUMAB;

ADULT; ALOPECIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; COLD SENSATION; COLORECTAL CANCER; CONTROLLED STUDY; COOLING; DIGESTIVE SYSTEM CANCER; FEMALE; FOLLOW UP; HEADACHE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NETHERLANDS; OBSERVATIONAL STUDY; OVARY CANCER; POST INFUSION SCALP COOLING TIME; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SCALP; VISUAL ANALOG SCALE;

ALOPECIA; ANTINEOPLASTIC AGENTS; CRYOTHERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT SATISFACTION; SCALP DERMATOSES; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84868500897     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1465-0     Document Type: Article

References (27)

1. Grevelman EG, Breed WP (2005) Prevention of chemotherapyinduced hair loss by scalp cooling. Ann Oncol 16:352-358
2. BreedWPM, van den Hurk CJG, Peerbooms M(2011) Presentation, impact and prevention of chemotherapy-induced hair loss; scalp cooling potentials and limitations. Expert Rev Dermatol 6:109-125
3. Christodoulou C, Klouvas G, Efstathiou E et al (2002) Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia. Oncology 62:97-102
4. Katsimbri P, Bamias A, Pavlidis N (2000) Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur J Cancer 36:766-771
5. Lemenager M, Lecomte S, Bonneterre ME et al (1997) Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. Eur J Cancer 33:297-300
6. Lundgren-Eriksson L, Edbom G, Olofsson Y et al (1999) Total prevention of taxoid-induced alopecia by a new model of cold cap (dignitana). Eur J Cancer 35(suppl 4):376
7. Auvinen PK, Mahonen UA, Soininen KM et al (2010) The effectiveness of a scalp cooling cap in preventing chemotherapyinduced alopecia. Tumori 96:271-275
8. Ridderheim M, Bjurberg M, Gustavsson A (2003) Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients. Support Care Cancer 11:371-377
9. ElGenidiM(2001) Prevention of chemotherapy-induced alopecia by the new digital scalp cooler device. Eur J Cancer 37(Suppl 6):357
10. Massey CS (2004) A multicentre study to determine the efficacy and patient acceptability of the Paxman Scalp Cooler to prevent hair loss in patients receiving chemotherapy. Eur J Oncol Nurs 8:121-130
11. Cortes JE, Pazdur R (1995) Docetaxel. J Clin Oncol 13:2643-2655
12. Middleton J, Franks D, Buchanan RB et al (1985) Failure of scalp hypothermia to prevent hair loss when cyclophosphamide is added to doxorubicin and vincristine. Cancer Treat Rep 69:373-375
13. Hilton S, Hunt K, Emslie C et al (2008) Have men been overlooked? A comparison of young men and women's experiences of chemotherapy-induced alopecia. Psycho-Oncology 17:577-583
14. Baxley KO, Erdman LK, Henry EB, Roof BJ (1984) Alopecia: effect on cancer patients' body image. Cancer Nurs 7:499-503
15. de Boer-Dennert M, de Wit R, Schmitz PI et al (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055-1061
16. Tabernero J, Climent MA, Lluch A et al (2004) A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15:1358-1365
17. Ravdin PM, Burris HA 3rd, Cook G et al (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedioneresistant breast cancer. J Clin Oncol 13:2879-2885
18. MartyM, Cognetti F,MaraninchiDet al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2- positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265-4274
19. O'Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812-2823
20. Sjostrom J, Blomqvist C, Mouridsen H et al (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35:1194-1201
21. Chan S, Friedrichs K, Noel D et al (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354
22. Chevallier B, Fumoleau P, Kerbrat P et al (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314-322
23. Bonneterre J, Roche H, Monnier A et al (2002) Docetaxel vs 5- fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 87:1210-1215
24. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
25. Fossella F, Pereira JR, von Pawel J et al (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-smallcell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016-3024
26. Chang HR, Glaspy J, Allison MA et al (2010) Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 116:4227-4237
27. van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, Nortier JW, Coebergh JW, Breed WP (2012) Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - Results of the Dutch Scalp Cooling Registry. Acta Oncol 51(4):497-504